Standard disease assessments at the 18th month of oral TKI administration for the chronic-phase CML patient include critical clinical evaluation to establish CHR and CCyR, and quantitative molecular BCR-ABL analyses to identify molecular response [12]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.